APA (7th ed.) Citation

Daniel Heudobler, Daniel Heudobler, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, . . . Albrecht Reichle. (2021). A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Daniel Heudobler, et al. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A., 2021.

MLA (9th ed.) Citation

Daniel Heudobler, et al. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A., 2021.